Eurofins BioPharma Product Testing Leiden B.V., part of the Eurofins network of BioPharma Product Testing (BPT) companies in the Netherlands, has opened a new state-of-the-art GMP testing and manufacturing facility at the Leiden Bio Science Park. Bringing together analytical chemistry, microbiology, biosafety testing and GMP-aligned manufacturing under one roof, the new site represents a significant investment in scientific excellence, operational efficiency, and customer support.
Spanning 11,600 m², the facility consolidates multiple laboratories into a single integrated site designed to support biopharmaceutical companies from early-stage development through to commercial release. By combining complementary expertise and services in one location, Eurofins BPT enables faster communication, streamlined project management and more efficient execution of complex development programmes.
The facility supports both biologics and small molecules and offers a comprehensive portfolio of analytical, microbiological, biosafety, manufacturing, and release services. Customers benefit from a single point of contact and seamless access to multidisciplinary expertise, simplifying technology transfer and reducing the complexity often associated with managing multiple service providers.
As part of the global Eurofins BioPharma Product Testing network, the Leiden site combines local scientific expertise with international resources and capabilities. This integrated approach provides customers with the flexibility, scalability and technical support needed to navigate increasingly complex regulatory and development challenges.
Located in one of Europe’s leading life sciences hubs, the facility has been designed with future growth in mind. Advanced laboratories, modern cleanroom infrastructure, expanded capacity and dedicated space for future expansion position the site to support emerging therapies and evolving industry requirements for years to come.
More than a new facility, this investment reinforces the Eurofins network’s commitment to helping customers accelerate the development and release of safe, effective medicines. By bringing critical services together under one roof, the Leiden site creates a more connected, agile, and efficient environment for innovation, ultimately accelerating the delivery of life-changing therapies to patients worldwide.
Contact us or visit our webpage to find out more.